Repression of SRF target genes is critical for Myc‐dependent apoptosis of epithelial cells

Oncogenic levels of Myc expression sensitize cells to multiple apoptotic stimuli, and this protects long‐lived organisms from cancer development. How cells discriminate physiological from supraphysiological levels of Myc is largely unknown. Here, we show that induction of apoptosis by Myc in breast epithelial cells requires association of Myc with Miz1. Gene expression and ChIP‐Sequencing experiments show that high levels of Myc invade target sites that lack consensus E‐boxes in a complex with Miz1 and repress transcription. Myc/Miz1‐repressed genes encode proteins involved in cell adhesion and migration and include several integrins. Promoters of repressed genes are enriched for binding sites of the serum‐response factor (SRF). Restoring SRF activity antagonizes Myc repression of SRF target genes, attenuates Myc‐induced apoptosis, and reverts a Myc‐dependent decrease in Akt phosphorylation and activity, a well‐characterized suppressor of Myc‐induced apoptosis. We propose that high levels of Myc engage Miz1 in repressive DNA binding complexes and suppress an SRF‐dependent transcriptional program that supports survival of epithelial cells.

[1]  Raluca Gordân,et al.  Sequence specificity incompletely defines the genome-wide occupancy of Myc , 2014, Genome Biology.

[2]  J. Bultinck,et al.  Tumor cell-specific inhibition of MYC function using small molecule inhibitors of the HUWE1 ubiquitin ligase , 2014, EMBO molecular medicine.

[3]  G. Evan,et al.  BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. , 2014, Cell reports.

[4]  L. Zender,et al.  Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles , 2014, Nature.

[5]  Marco J. Morelli,et al.  Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis , 2014, Nature.

[6]  R. Treisman,et al.  Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts , 2014, Genes & development.

[7]  O. Sansom,et al.  The role of MIZ-1 in MYC-dependent tumorigenesis. , 2013, Cold Spring Harbor perspectives in medicine.

[8]  M. Roussel,et al.  Miz1 is required to maintain autophagic flux , 2013, Nature Communications.

[9]  W. Gu,et al.  Differential effects on ARF stability by normal versus oncogenic levels of c-Myc expression. , 2013, Molecular cell.

[10]  Tak W. Mak,et al.  Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. , 2013, Genes & development.

[11]  Anni I. Nieminen,et al.  Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis , 2013, Proceedings of the National Academy of Sciences.

[12]  J. Sznajder,et al.  Suppression of inflammation and acute lung injury by the transcription factor Miz1 via repression of C/EBP-δ , 2013, Nature Immunology.

[13]  Scot R. Kimball,et al.  Role of p70S6K1-mediated Phosphorylation of eIF4B and PDCD4 Proteins in the Regulation of Protein Synthesis* , 2012, The Journal of Biological Chemistry.

[14]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[15]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[16]  D. Radisky,et al.  MYC Suppresses Cancer Metastasis by Direct Transcriptional Silencing of αv and β3 Integrin Subunits , 2012, Nature Cell Biology.

[17]  Marc E. Lenburg,et al.  MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition , 2012, The Journal of experimental medicine.

[18]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[19]  Sarat Chandarlapaty,et al.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling. , 2011, Cancer discovery.

[20]  A. Redig,et al.  Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors , 2011, Clinical Cancer Research.

[21]  M. Troxell,et al.  Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. , 2011, Cancer research.

[22]  G. Wahl,et al.  Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures , 2010, Proceedings of the National Academy of Sciences.

[23]  P. Majumder,et al.  MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo , 2010, Molecular Cancer Therapeutics.

[24]  D. Felsher,et al.  The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. , 2010, Genes & development.

[25]  A. Orian,et al.  The Arf tumor suppressor protein inhibits Miz1 to suppress cell adhesion and induce apoptosis , 2010, The Journal of cell biology.

[26]  C. Dang,et al.  Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model , 2010, Proceedings of the National Academy of Sciences.

[27]  B. Hemmings,et al.  Protein kinase B (PKB/Akt), a key mediator of the PI3K signaling pathway. , 2010, Current topics in microbiology and immunology.

[28]  P. Fortina,et al.  p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo , 2009, Proceedings of the National Academy of Sciences.

[29]  G. Evan,et al.  Distinct thresholds govern Myc's biological output in vivo. , 2008, Cancer cell.

[30]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[31]  Z. Xuan,et al.  Deregulation of Scribble Promotes Mammary Tumorigenesis and Reveals a Role for Cell Polarity in Carcinoma , 2008, Cell.

[32]  N. D. Clarke,et al.  Integration of External Signaling Pathways with the Core Transcriptional Network in Embryonic Stem Cells , 2008, Cell.

[33]  T. Mäkelä,et al.  Suppression of oncogenic properties of c-Myc by LKB1-controlled epithelial organization , 2007, Proceedings of the National Academy of Sciences.

[34]  Nicola Zamboni,et al.  Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells , 2007, The Journal of cell biology.

[35]  R. Treisman,et al.  Nuclear Actin Regulates Dynamic Subcellular Localization and Activity of the SRF Cofactor MAL , 2007, Science.

[36]  J. Partanen,et al.  c‐Myc primed mitochondria determine cellular sensitivity to TRAIL‐induced apoptosis , 2007, The EMBO journal.

[37]  Pierre Lavigne,et al.  The mechanism of discrimination between cognate and non-specific DNA by dimeric b/HLH/LZ transcription factors. , 2007, Journal of molecular biology.

[38]  S. McMahon,et al.  BCL2 Is a Downstream Effector of MIZ-1 Essential for Blocking c-MYC-induced Apoptosis* , 2007, Journal of Biological Chemistry.

[39]  Nils Cordes,et al.  Signalling via integrins: implications for cell survival and anticancer strategies. , 2007, Biochimica et biophysica acta.

[40]  Zhiping Weng,et al.  Global mapping of c-Myc binding sites and target gene networks in human B cells , 2006, Proceedings of the National Academy of Sciences.

[41]  R. Treisman,et al.  Actin' together: serum response factor, its cofactors and the link to signal transduction. , 2006, Trends in cell biology.

[42]  Giacomo Finocchiaro,et al.  Myc-binding-site recognition in the human genome is determined by chromatin context , 2006, Nature Cell Biology.

[43]  S. McMahon,et al.  Targeting of Miz-1 Is Essential for Myc-mediated Apoptosis* , 2006, Journal of Biological Chemistry.

[44]  F. Watt,et al.  Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1 , 2006, The Journal of cell biology.

[45]  J. Schouten,et al.  High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model , 2006, Breast Cancer Research and Treatment.

[46]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[48]  P. Hall,et al.  An expression signature for p 53 status in human breast cancer predicts mutation status , transcriptional effects , and patient survival , 2005 .

[49]  S. Dedhar,et al.  Integrin-linked kinase: a cancer therapeutic target unique among its ILK , 2005, Nature Reviews Cancer.

[50]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[51]  Mark J. Murphy,et al.  c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. , 2004, Genes & development.

[52]  S. Johansson,et al.  β1‐Integrins induce phosphorylation of Akt on serine 473 independently of focal adhesion kinase and Src family kinases , 2004, EMBO reports.

[53]  B. Clurman,et al.  The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Marc Nasoff,et al.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.

[55]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[57]  J. Bishop,et al.  Negative Control of the Myc Protein by the Stress-Responsive Kinase Pak2 , 2004, Molecular and Cellular Biology.

[58]  John L Cleveland,et al.  Myc pathways provoking cell suicide and cancer , 2003, Oncogene.

[59]  Jayanta Debnath,et al.  Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.

[60]  S. Dedhar,et al.  Conditional Knock-out of Integrin-linked Kinase Demonstrates an Essential Role in Protein Kinase B/Akt Activation* , 2003, Journal of Biological Chemistry.

[61]  R. Treisman,et al.  Actin Dynamics Control SRF Activity by Regulation of Its Coactivator MAL , 2003, Cell.

[62]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[63]  Kenneth M. Yamada,et al.  Fibronectin, integrins, and growth control , 2001, Journal of cellular physiology.

[64]  U. Weidle,et al.  The transcriptional program of a human B cell line in response to Myc. , 2001, Nucleic acids research.

[65]  T. Pollard,et al.  Actin dynamics. , 2001, Journal of cell science.

[66]  M. Roussel,et al.  Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. , 1999, Genes & development.

[67]  G. Cohn,et al.  Spontaneous conversion to estrogen receptor expression by the human breast epithelial cell line, MCF-10A. , 1999, Oncology Report.

[68]  S. Salghetti,et al.  Destruction of Myc by ubiquitin‐mediated proteolysis: cancer‐associated and transforming mutations stabilize Myc , 1999, The EMBO journal.

[69]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[70]  R. Treisman,et al.  Activation of SRF-Regulated Chromosomal Templates by Rho-Family GTPases Requires a Signal that Also Induces H4 Hyperacetylation , 1998, Cell.

[71]  A. Giaccia,et al.  p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts , 1998, Cell Death and Differentiation.

[72]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[73]  J. Brugge,et al.  Phosphatidylinositol 3-kinase is required for integrin-stimulated AKT and Raf-1/mitogen-activated protein kinase pathway activation , 1997, Molecular and cellular biology.

[74]  Asim Khwaja,et al.  Matrix adhesion and Ras transformation both activate a phosphoinositide 3‐OH kinase and protein kinase B/Akt cellular survival pathway , 1997, The EMBO journal.

[75]  G. Evan,et al.  Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB , 1997, Nature.

[76]  G. Evan,et al.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. , 1995, Nucleic acids research.

[77]  H. Hermeking,et al.  Mediation of c-Myc-induced apoptosis by p53. , 1994, Science.

[78]  G. Evan,et al.  The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. , 1993, The EMBO journal.

[79]  A Ma,et al.  Binding of myc proteins to canonical and noncanonical DNA sequences , 1993, Molecular and cellular biology.

[80]  Gerard I. Evan,et al.  Induction of apoptosis in fibroblasts by c-myc protein , 1992, Cell.

[81]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[82]  Didier Picard,et al.  Chimaeras of Myc oncoprotein and steroid receptors cause hormone-dependent transformation of cells , 1989, Nature.